Table 2.
Pathologic Characteristics of Patients Treated Who Underwent Enucleation (n = 82)
| Characteristic | Data |
|---|---|
| Sex | |
| Male | 45 (55) |
| Female | 37 (45) |
| Age at diagnosis (yrs), mean (range) | 62 (28–88) |
| Follow-up time (mos), median/mean (range) | 23/49 (0–272) |
| Metastasis | |
| No | 43 (52) |
| Yes | 39 (48) |
| Tumor diameter (mm), mean (range) | 13.4 (3–23) |
| Cell type | |
| Spindle cell | 27 (33) |
| Epithelioid | 13 (16) |
| Mixed | 42 (51) |
| Primary tumor location | |
| Choroid | 66 (81) |
| Ciliary body | 16 (19) |
| BAP1 staining results | |
| Negative | 40 (49) |
| Positive | 28 (34) |
| Not determined | 14 (17) |
| AJCC T classification | |
| T1 | 11 (13) |
| T2 | 24 (29) |
| T3 | 38 (47) |
| T4 | 9 (11) |
| Pretreatment NLR, median (SD) | 2.72 (1.47) |
| Pretreatment LMR, median (SD) | 3.28 (1.38) |
AJCC = American Joint Committee on Cancer; LMR = lymphocyte-to-monocyte ratio; NLR = neutrophil-to-lymphocyte ratio; SD = standard deviation.
Data are presented as no. (%), unless otherwise indicated.